Related Experiment Video
Updated: Mar 20, 2026

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons
Published on: August 23, 2016
Effect and side-effects of alpha interferon treatment in haemophilia patients with chronic hepatitis C
E P Mauser-Bunschoten1, D Bresters1, H W Reesink1
1Van Creveld Clinic, University Hospital Utrecht; Department of Virus Diagnostics, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam; Department of Hepato-gastroenterology, Academic Medical Centre, Amsterdam, The Netherlands.
To evaluate the effect and side-effects of alpha interferon 2B (IFN) treatment in haemophilia patients with chronic hepatitis C (positive HCV antibody test, positive HCV-RNA test and ALT levels >2.5 × upper limit of normal) eight HIV and HBs-ag negative haemophilia patients were treated with IFN for 26 weeks in a dosage of 5 mega units (MU) daily for 2 weeks, 2.5 MU daily for 4 weeks and 1.5 MU 3 times a week for 20 weeks. Patients who were transient or non-responders after 26 weeks of IFN therapy were treated for 2.5 years with 5 MU IFN three times a week. At the end of 3 years follow-up, four patients were considered complete responders (HCV-RNA negative) with complete and sustained ALT normalization and disappearance from HCV-RNA from blood, two patients only showed a transient response and two patients were non-responders. All patients experienced the common side-effects of IFN treatment. Two patients complained about feelings of depression and impotence. For both this was the reason to stop IFN treatment. In one patient, IFN treatment was stopped 90 weeks after start of therapy because of persistent fatigue. In another patient the dosage was adjusted because of a decrease in platelet count. No effect of IFN on bleeding frequency and chronic arthopathy was seen. We conclude that the clinical effects and side-effects of IFN therapy in patients with haemophilia and chronic hepatitis C are comparable with those of non-haemophilia patients with chronic hepatitis C. Haemophilia patients can be treated for chronic hepatitis C infection in the same way as patients without haemophilia.
To evaluate the effect and side-effects of alpha interferon 2B (IFN) treatment in haemophilia patients with chronic hepatitis C (positive HCV antibody test, positive HCV-RNA test and ALT levels >2.5 × upper limit of normal) eight HIV and HBs-ag negative haemophilia patients were treated with IFN for 26 weeks in a dosage of 5 mega units (MU) daily for 2 weeks, 2.5 MU daily for 4 weeks and 1.5 MU 3 times a week for 20 weeks. Patients who were transient or non-responders after 26 weeks of IFN therapy were treated for 2.5 years with 5 MU IFN three times a week. At the end of 3 years follow-up, four patients were considered complete responders (HCV-RNA negative) with complete and sustained ALT normalization and disappearance from HCV-RNA from blood, two patients only showed a transient response and two patients were non-responders. All patients experienced the common side-effects of IFN treatment. Two patients complained about feelings of depression and impotence. For both this was the reason to stop IFN treatment. In one patient, IFN treatment was stopped 90 weeks after start of therapy because of persistent fatigue. In another patient the dosage was adjusted because of a decrease in platelet count. No effect of IFN on bleeding frequency and chronic arthopathy was seen. We conclude that the clinical effects and side-effects of IFN therapy in patients with haemophilia and chronic hepatitis C are comparable with those of non-haemophilia patients with chronic hepatitis C. Haemophilia patients can be treated for chronic hepatitis C infection in the same way as patients without haemophilia.
More Related Videos
07:25Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
06:28Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
Published on: October 1, 2015
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Hepatitis
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Anticoagulant Drugs: Low-Molecular-Weight Heparins